小智港股覆盤 | 2月11日
今日，港股三大指數集體下跌。截止收盤，恆生指數跌0.07%，報24906點。國企指數跌0.06%，報8784點。恆生科技指數跌1.23%，報5597點。市場約662只個股上漲，1062只個股下跌。成交額突破1392.41億港幣，和昨天同期相比增長7.83%。南下資金淨流出3.92億港幣。
盤面上，商業服務板塊走高。金茂源環保漲超22%；信能低碳漲超9%；中國綠地博大綠澤、吉輝控股等多股漲超8%；金涌投資漲超5%。
食品零售板塊跟隨走強。高鑫零售、香港食品投資等多股漲超3%；優品360、CEC INT'L HOLD、聯華超市等多股漲超1%。高鑫零售(6808.HK)反彈逾9%，市值重回300億港元上方。
飲料板塊活躍。百威亞太漲超3%；高銀金融漲超1%。高盛上調百威亞太目標價至24元，評級「買入」。
電氣設備板塊集體下挫。匯聚科技跌超12%；時代電氣跌超11%；濠亮環球跌超8%；金風科技、星凱控股等多股跌超4%。高盛削金風科技目標價5.3%至18港元，維持“中性”評級；星凱控股2月25日舉行董事會會議審批中期業績。
醫療設備板塊多數下跌。微創醫療跌超8%；沛嘉醫療-B、歸創通橋-B、愛康醫療等多股跌超6%；心瑋醫療-B跌超5%。微創醫療：附屬公司微創機器人計劃採納購股權計劃；心瑋醫療-B擬斥資3480萬元入股上海御瓣醫療科技,加強心臟介入佈局,將產品覆蓋面擴大至結構性心臟病治療領域。
生物科技板塊多數下跌。雲頂新耀-B跌超10%；歌禮制藥-B、亞盛醫藥-B等多股跌超8%；康方生物-B、康寧傑瑞製藥-B等多股跌超7%。歌禮制藥-B高開逾7%，自主研發的抗病毒口服藥物ASC10在臨牀試驗中對新冠肺炎的療效可能比莫努匹韋更好；康方生物-B自研NGF單抗(AK115)治療疼痛臨牀試驗獲批；康寧傑瑞製藥-B：KN052及KN046II期臨牀試驗獲國家藥監局兩項IND批準。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
